GlassScriptPhysician profile
Robyn Glass
NPI 1790236636
$5,822.32
in general payments reported to CMS, 2019-2025
19 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $879 · 2021: $693 · 2022: $881 · 2023: $1,105 · 2024: $881 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,000 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,999.66 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $998.07 | 2019-2025 | Tryptyr, Total30, Clareon |
| Abbvie INC. | $728.58 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $450.95 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Biotissue Holdings INC. | $447.41 | 2024-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $443.21 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $439.30 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $403.66 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $385.91 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $330.22 | 2023-2025 | Tyrvaya |
| Allergan, INC. | $290.63 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $195.70 | 2020-2022 | |
| Harrow Eye, LLC | $145.47 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $133.62 | 2019-2021 | |
| Dompe US, INC. | $104.65 | 2024-2025 | Oxervate |
| Coopervision INC. | $102.81 | 2021-2025 | Myday Contact Lens, Clariti Contact Lens |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $95.67 | 2022-2025 | |
| Notal Vision, INC. | $94.91 | 2022 | |
| Amgen INC. | $17.00 | 2024 | Tepezza |
| Shire North American Group INC | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Glass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.